ArticleAnnals of medicine and surgery (2012)2025
Analysis of the pharmacological mechanisms of Xiaoyao pill in breast cancer treatment.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The Xiaoyao pill, a Chinese patent medicine initially designed for treating breast hyperplasia, has emerged as a potential therapy for inhibiting breast cancer. Method: Research has delved into its mechanisms, utilizing Disease Oncology, Gene Oncology, and Kyoto Encyclopedia of Genes and Genomes analyses. Correlations between Xiaoyao pill's target genes and lipid metabolism were identified. Comparative gene set enrichment analysis between normal and breast cancer (BRCA) tissues showed down-regulation of lipid metabolism-related genes in BRCA, suggesting their role in cancer development. Weighted gene co-expression analysis revealed a gene module associated with both normal and malignant breast tissue, impacting lipid metabolism significantly. Result: Protein-protein interaction network analysis highlighted expression differences in 24 common genes shared between Xiaoyao pill and BRCA. Receiver operating characteristic curve analysis indicated Xiaoyao pill's potential diagnostic utility for BRCA. Target genes were detectable in immune cell types, particularly T cells, suggesting a role in tumor immunity modulation. Conclusion: In conclusion, the Xiaoyao pill holds promise in treating BRCA by down-regulating lipid metabolism pathways and potentially influencing tumor immunity, presenting a multifaceted approach to breast cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.